Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ceftriaxone Clear all
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media

NCT02567825
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Tympanostomy tube placement, Amoxicillin-Clavulanate and/or Ceftriaxone, Ofloxacin Otic
Device · Drug
Lead sponsor
Alejandro Hoberman
Other
Eligibility
6 Months to 35 Months
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 4 Interventional

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

NCT03560232
View directory record Official record
Conditions
Open Fracture, Post-Op Wound Infection
Interventions
Ceftriaxone, Ampicillin/sulbactam, Piperacillin/tazobactam, Cefazolin + Gentamicin, Clindamycin + Gentamicin
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Warren, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

NCT00195351
View directory record Official record
Conditions
Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
Interventions
tigecycline, ceftriaxone sodium + metronidazole
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
46
States / cities
Mobile, Alabama • Laguna Hills, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 2, 2026, 4:37 AM EDT
Recruiting Phase 4 Interventional

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

NCT06396078
View directory record Official record
Conditions
Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth
Interventions
Ceftriaxone 1000 MG, Clarithromycin 500mg, Metronidazole 500 mg, Ampicillin 2 GM Injection, Amoxicillin 250 MG, Azithromycin, Erythromycin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Columbus, Ohio • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae

NCT03840811
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 36 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Brain Imaging and Retreatment Study of Persistent Lyme Disease

NCT00037479
View directory record Official record
Conditions
Lyme Disease, Lyme Neuroborreliosis
Interventions
ceftriaxone
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2005 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 4 Interventional Results available

Early Antibiotics After Aspiration in ICU Patients

NCT05079620
View directory record Official record
Conditions
Aspiration, Aspiration Pneumonia
Interventions
Ceftriaxone, Amoxicillin clavulanic acid, Cefepime, Vancomycin, Levofloxacin
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

NCT02419001
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB, Period 2 - Treatment Sequence AC
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

NCT04999592
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Pneumonia
Interventions
Standard of care without prophylaxis, Antibiotic prophylaxis
Drug
Lead sponsor
David J. Gagnon
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 2, 2026, 4:37 AM EDT
Completed No phase listed Observational

Chlamydia Trachomatis Immunology and Vaccinology Study

NCT01150747
View directory record Official record
Conditions
Chlamydia
Interventions
ceftriaxone, Azithromycin
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 4 Interventional

Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia

NCT00358202
View directory record Official record
Conditions
Pneumonia
Interventions
cefepime, ceftriaxone
Drug
Lead sponsor
CPL Associates
Other
Eligibility
60 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

NCT00111644
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Ceftriaxone, beta-lactam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 2, 2026, 4:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

NCT01160640
View directory record Official record
Conditions
Pelvic Inflammatory Disease
Interventions
Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule
Drug
Lead sponsor
Harold Wiesenfeld
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Zoliflodacin in Uncomplicated Gonorrhoea

NCT03959527
View directory record Official record
Conditions
Gonorrhea
Interventions
zoliflodacin, ceftriaxone, azithromycin
Drug
Lead sponsor
Global Antibiotics Research and Development Partnership
Other
Eligibility
12 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])

NCT02384200
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infections
Interventions
nitrofurantoin monohydrate/macrocrystalline capsules, ampicillin, gentamicin, vancomycin, ceftriaxone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

NCT02210325
View directory record Official record
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, ceftriaxone, azithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

NCT04010539
View directory record Official record
Conditions
Gonorrhea
Interventions
Gepotidacin, Ceftriaxone, Azithromycin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 2, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Ceftriaxone in Subjects With ALS

NCT00349622
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
ceftriaxone, placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
50
States / cities
Phoenix, Arizona • Davis, California • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 2, 2026, 4:37 AM EDT